Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vaccinating Children After Chemotherapy for Acute Lymphoblastic Leukemia: A Canadian Immunization Research Network Study

Trial Profile

Vaccinating Children After Chemotherapy for Acute Lymphoblastic Leukemia: A Canadian Immunization Research Network Study

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Feb 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hib-DTaP-poliovirus vaccine (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Pneumococcal vaccine (Primary)
  • Indications Pertussis; Pneumonia; Poliomyelitis; Varicella zoster virus infections
  • Focus Pharmacodynamics
  • Most Recent Events

    • 17 Jan 2021 Status changed from active, no longer recruiting to completed.
    • 18 Feb 2020 Primary endpoint has been met. (GMCs at 2 and 12 months post-booster vaccination versus baseline among participants treated for ALL)
    • 18 Feb 2020 Primary endpoint has been met. (Geometric mean antibody concentrations (GMCs) to 10 PCV serotypes, PT, TT and varicella in participants treated for ALL versus controls)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top